2 ASX healthcare names still holding up better than the market

The following 2 ASX healthcare stocks still holding up better than the market :- 

Ramsay Health Care Limited (ASX: RHC)

Ramsay Health Care Limited (ASX: RHC) engages in the healthcare services and the operation of hospitals and day surgery facilities. It operates through the following geographical segments Australia, UK, France and Nordics.

FY26 revenue has increased by 4.2% to $18.6 billion we can see that the revenue is increasing each year at a good pace which shows the company is growing and having better utilization which is supported by stronger activity across its regions also the underlying EBIT rose 11.8% to $1.16 billion with the underlying NPAT increasing 22.9% to $364.1 million which in turn reflects improved operating performance and efficiency initiatives. The reported NPAT also improved significantly to $329.2 million, compared with $24 million in FY25.

Australia has remained an important contributor with the revenue growth of 7.8% and underlying EBIT increasing 11.2% along with Australia the UK business also recorded stronger underlying earnings while Ramsay Sante delivered improved performance across Europe. Looking ahead, Ramsay expects further EBIT growth and margin improvement in its Funding Group during FY27 which would be supported by higher patient activity better hospital utilisation and ongoing operational improvements.

In the recent 2030 guidance it was announced that the future plan will be built on the 2015 and 2021 plans, shifting from expansion and platform integration to unlocking the platform’s potential through profitable growth and medical excellence meanwhile improving operations and stepping into digitalisation.

Ansell Limited (ASX: ANN)

Ansell Limited (ASX: ANN) engages in the development along with manufacturing and distribution and even sale of gloves and protective solutions. It operates through the Healthcare and Industrial segment and in this the Healthcare segment includes surgical and examination gloves along with healthcare safety devices and active infection prevention products for healthcare patients and single use industrial application gloves.

FY26 revenue has increased by 6.8% to US$2.14 billion, compared with US$2.00 billion in FY25 this shows us better sales and performance of the company and utilization of underlying potential with there Adjusted EBIT rose 14.1% to US$321.9 million, while adjusted EBIT margin improved to 15.0% from 14.1% all of this reflecting stronger sales and improved operating efficiency along with getting a strong hold in the market the company’s net profit attributable to shareholders has been doubled to US$208.6 million, compared with US$101.6 million in the previous year which shows company would be able to sustain in the longer run with better profit margins.

Looking ahead Ansell expects more and better sales growth in FY27 supported by higher volumes with the pricing initiatives they and continued demand across strategic markets and targeted industries particularly the US and scientific sectors. The company also aims to improve earnings through operational efficiencies so they can utilise the potential and productivity initiatives are being carried on and a focus on higher-margin products is being given.

(Source: Company Announcements)